{"filing":{"accession_number":"0001104659-26-075440","cik":"0001829635","ticker":"RNAZ","company_name":"Transcode Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-18","report_date":null,"primary_document":"tm2618153d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926075440/tm2618153d1_8k.htm"},"events":[{"id":11705,"run_id":10288,"accession_number":"0001104659-26-075440","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"TransCode posted a corporate presentation to its website on June 18, 2026, disclosing clinical trial progress (Phase 1a and Phase 2a data for TTX-MC138, Phase 3 status for Seviprotimut-L vaccine), pipeline details, and management/advisory board information. While the presentation contains material clinical and operational information relevant to investors, it does not fit neatly into the standard 8-K event categories (no earnings release, executive change, M\u0026A, restatement, impairment, or other discrete triggering event). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) as a non-filed investor presentation, making it a material corporate communication that falls outside the more specific taxonomy.","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-06-18","form":"8-K","submitted_at":null,"items":[{"id":8360,"accession_number":"0001104659-26-075440","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"TransCode posted a corporate presentation to its website on June 18, 2026, disclosing clinical trial progress (Phase 1a and Phase 2a data for TTX-MC138, Phase 3 status for Seviprotimut-L vaccine), pipeline details, and management/advisory board information. While the presentation contains material clinical and operational information relevant to investors, it does not fit neatly into the standard 8-K event categories (no earnings release, executive change, M\u0026A, restatement, impairment, or other discrete triggering event). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) as a non-filed investor presentation, making it a material corporate communication that falls outside the more specific taxonomy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:02:11.075435+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8360,"accession_number":"0001104659-26-075440","item_number":"7.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"TransCode posted a corporate presentation to its website on June 18, 2026, disclosing clinical trial progress (Phase 1a and Phase 2a data for TTX-MC138, Phase 3 status for Seviprotimut-L vaccine), pipeline details, and management/advisory board information. While the presentation contains material clinical and operational information relevant to investors, it does not fit neatly into the standard 8-K event categories (no earnings release, executive change, M\u0026A, restatement, impairment, or other discrete triggering event). The disclosure is furnished under Item 7.01 (Regulation FD Disclosure) as a non-filed investor presentation, making it a material corporate communication that falls outside the more specific taxonomy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-18T12:02:11.075435+00:00","company_name":"Transcode Therapeutics, Inc.","ticker":"RNAZ","filing_date":"2026-06-18"}]}